Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?

被引：5

作者：

Ayala-de Miguel, Carlos ^{[1
]}

Jimenez-Castro, Jeronimo ^{[1
]}

Sanchez-Vegas, Adrian ^{[1
]}

Diaz-Lopez, Sebastian ^{[1
]}

Chaves-Conde, Manuel ^{[1
]}

机构：

[1] Hosp Univ Virgen Valme, Serv Oncol Med, De Cadiz Km 548,9, Seville 41014, Spain

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2024年 / 202卷

关键词：

Colorectal cancer; Third-line; TAS-102; Bevacizumab; Anti-EGFR; Regorafenib; Fruquintinib; Trastuzumab-deruxtecan; PIPAC; INTRAPERITONEAL AEROSOL CHEMOTHERAPY; BEVACIZUMAB PLUS CHEMOTHERAPY; MISMATCH REPAIR-DEFICIENT; POSITIVE SOLID TUMORS; DRUG-ELUTING BEADS; LATER-LINE THERAPY; PHASE-III TRIAL; OPEN-LABEL; 1ST-LINE TREATMENT; LIVER METASTASES;

D O I：

10.1016/j.critrevonc.2024.104454

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer remains the third most common cancer worldwide and the second cause of cancer-related death. Treatment advances and precision oncological medicine for these tumours have been stalled in comparison to those for other common tumours such as lung and breast cancer. However, the recent publication of the SUNLIGHT trial results with the trifluridine/tipiracil (TAS-102)-bevacizumab combination and the irruption of new molecular targets with guided treatments have opened new possibilities in third-line metastatic colorectal cancer management. Anti-EGFR rechallenge, anti-HER2 targeted therapies or the promising results of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC), are some of the available options that may modify what is presumably third-line colorectal treatment. Hereby, we present the evidence of the different treatment options in third-line colorectal cancer and beyond, as well as the possibilities of sequencing them.

引用

页数：16

共 128 条

[71] Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials [J].

Martini, G. ;

Ciardiello, D. ;

Famiglietti, V. ;

Rossini, D. ;

Antoniotti, C. ;

Troiani, T. ;

Napolitano, S. ;

Esposito, L. ;

Latiano, T. P. ;

Maiello, E. ;

Del Re, M. ;

Lonardi, S. ;

Aprile, G. ;

Santini, D. ;

Masi, G. ;

Avallone, A. ;

Normanno, N. ;

Pietrantonio, F. ;

Pinto, C. ;

Ciardiello, F. ;

Cremolini, C. ;

Martinelli, E. .

CANCER MEDICINE, 2023, 12 (08) :9392-9400

[72] Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment inKRASwild-type metastatic colorectal cancer: JACCRO CC-08 [J].

Masuishi, Toshiki ;

Tsuji, Akihito ;

Kotaka, Masahito ;

Nakamura, Masato ;

Kochi, Mitsugu ;

Takagane, Akinori ;

Shimada, Ken ;

Denda, Tadamichi ;

Segawa, Yoshihiko ;

Tanioka, Hiroaki ;

Hara, Hiroki ;

Sagawa, Tamotsu ;

Watanabe, Takanori ;

Takahashi, Takao ;

Negoro, Yuji ;

Manaka, Dai ;

Fujita, Hideto ;

Suto, Takeshi ;

Takeuchi, Masahiro ;

Ichikawa, Wataru ;

Fujii, Masashi .

BRITISH JOURNAL OF CANCER, 2020, 123 (10) :1490-1495

[73] Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies [J].

Mauri, Gianluca ;

Pizzutilo, Elio Gregory ;

Amatu, Alessio ;

Bencardino, Katia ;

Palmeri, Laura ;

Bonazzina, Erica Francesca ;

Tosi, Federica ;

Stella, Giulia Carlo ;

Burrafato, Giovanni ;

Scaglione, Francesco ;

Marsoni, Silvia ;

Siravegna, Giulia ;

Bardelli, Alberto ;

Siena, Salvatore ;

Sartore-Bianchi, Andrea .

CANCER TREATMENT REVIEWS, 2019, 73 :41-53

[74] Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer [J].

Mayer, Robert J. ;

Hochster, Howard S. ;

Cohen, Steven J. ;

Winkler, Robert ;

Makris, Lukas ;

Grothey, Axel .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (06) :961-969

[75] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer [J].

Mayer, Robert J. ;

Van Cutsem, Eric ;

Falcone, Alfredo ;

Yoshino, Takayuki ;

Garcia-Carbonero, Rocio ;

Mizunuma, Nobuyuki ;

Yamazaki, Kentaro ;

Shimada, Yasuhiro ;

Tabernero, Josep ;

Komatsu, Yoshito ;

Sobrero, Alberto ;

Boucher, Eveline ;

Peeters, Marc ;

Tran, Ben ;

Lenz, Heinz-Josef ;

Zaniboni, Alberto ;

Hochster, Howard ;

Cleary, James M. ;

Prenen, Hans ;

Benedetti, Fabio ;

Mizuguchi, Hirokazu ;

Makris, Lukas ;

Ito, Masanobu ;

Ohtsu, Atsushi .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20) :1909-1919

[76] Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study [J].

Meric-Bemstam, Funda ;

Hurwitz, Herbert ;

Raghav, Kanwal Pratap Singh ;

McWilliams, Robert R. ;

Fakih, Marwan ;

VanderWalde, Ari ;

Swanton, Charles ;

Kurzrock, Razelle ;

Burris, Howard ;

Sweeney, Christopher ;

Bose, Ron ;

Spigel, David R. ;

Beattie, Mary S. ;

Blotner, Steven ;

Stone, Alyssa ;

Schulze, Katja ;

Cuchelkar, Vaikunth ;

Hainsworth, John .

LANCET ONCOLOGY, 2019, 20 (04) :518-530

[77] Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer [J].

Misale, Sandra ;

Yaeger, Rona ;

Hobor, Sebastijan ;

Scala, Elisa ;

Janakiraman, Manickam ;

Liska, David ;

Valtorta, Emanuele ;

Schiavo, Roberta ;

Buscarino, Michela ;

Siravegna, Giulia ;

Bencardino, Katia ;

Cercek, Andrea ;

Chen, Chin-Tung ;

Veronese, Silvio ;

Zanon, Carlo ;

Sartore-Bianchi, Andrea ;

Gambacorta, Marcello ;

Gallicchio, Margherita ;

Vakiani, Efsevia ;

Boscaro, Valentina ;

Medico, Enzo ;

Weiser, Martin ;

Siena, Salvatore ;

Di Nicolantonio, Federica ;

Solit, David ;

Bardelli, Alberto .

NATURE, 2012, 486 (7404) :532-U131

[78] Treatment of Metastatic Colorectal Cancer: ASCO Guideline [J].

Morris, Van K. ;

Kennedy, Erin B. ;

Baxter, Nancy N. ;

Benson, Al B., III ;

Cercek, Andrea ;

Cho, May ;

Ciombor, Kristen K. ;

Cremolini, Chiara ;

Davis, Anjee ;

Deming, Dustin A. ;

Fakih, Marwan G. ;

Gholami, Sepideh ;

Hong, Theodore S. ;

Jaiyesimi, Ishmael ;

Klute, Kelsey ;

Lieu, Christopher ;

Sanoff, Hanna ;

Strickler, John H. ;

White, Sarah ;

Willis, Jason A. ;

Eng, Cathy .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) :678-+

[79] Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1 [J].

Mur, Pilar ;

Viana-Errasti, Julen ;

Garcia-Mulero, Sandra ;

Magraner-Pardo, Lorena ;

Munoz, Ines G. ;

Pons, Tirso ;

Capella, Gabriel ;

Pineda, Marta ;

Feliubadalo, Lidia ;

Valle, Laura .

GENOME MEDICINE, 2023, 15 (01)

[80] Role ofPOLEandPOLD1in familial cancer [J].

Mur, Pilar ;

Garcia-Mulero, Sandra ;

del Valle, Jesus ;

Magraner-Pardo, Lorena ;

Vidal, August ;

Pineda, Marta ;

Cinnirella, Giacomo ;

Martin-Ramos, Edgar ;

Pons, Tirso ;

Lopez-Doriga, Adriana ;

Belhadj, Sami ;

Feliubadalo, Lidia ;

Munoz-Torres, Pau M. ;

Navarro, Matilde ;

Grau, Elia ;

Darder, Esther ;

Llort, Gemma ;

Sanz, Judit ;

Ramon y Cajal, Teresa ;

Balmana, Judith ;

Brunet, Joan ;

Moreno, Victor ;

Piulats, Josep M. ;

Matias-Guiu, Xavier ;

Sanz-Pamplona, Rebeca ;

Aligue, Rosa ;

Capella, Gabriel ;

Lazaro, Conxi ;

Valle, Laura .

GENETICS IN MEDICINE, 2020, 22 (12) :2089-2100

← 3 4 5 6 7 8 9 10 11 12 →